The first two announcements are pure fluff smarty, preliminary...

The first two announcements are pure fluff smarty, preliminary bench studies a long way off clinical, no one is going to buy based on them. You could release lab result after lab result and it won’t make one iota of difference. The second two are the one horse wonder... Fuji, great announcements but still management can’t sell it. We know why. 

CYP is a clinical stage bio and the share price reflects this. The only thing that’s going to sustain the price or push it is real deals. We all sit here waiting for Fuji to sign, but they have already indicated this will happen, not CYP, but Fuji themselves. So I Ask you smarts, what is going to stoke buyiing interest? Is there a left field partnership coming? I only hope so, as manage

ment need to prove they are up to the task, and return some respect from their shareholders....  otherwise the AGM could get very interesting.

Director loans = large Odour. The only air freshener here 

will be a real money deal.